Iksuda Therapeutics raises $47m to progress ADC pipeline
Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase I clinical trials
Read More
Tag: Iksuda Therapeutics
Iksuda Therapeutics exercises licensing rights from University of Goettingen
Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
